Abeona Therapeutics Inc. SEC filings ABEO
Abeona Therapeutics Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Oct 21, 2008. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 15, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 4, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Apr 27, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Apr 17, 2026 |
| DEF 14A | Proxy statement | Apr 9, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Nov 12, 2024 | Nov 12, 2024 |
| DEF 14A | Proxy statement | Mar 19, 2024 | Mar 19, 2024 |
| DEF 14A | Proxy statement | Apr 13, 2023 | Apr 13, 2023 |
| DEFA14A | Additional proxy material | Aug 4, 2022 | — |
| DEF 14A | Proxy statement | Jul 11, 2022 | Aug 17, 2022 |
| DEF 14A | Proxy statement | May 12, 2022 | Jun 14, 2022 |
| PRE 14A | Preliminary proxy statement | May 2, 2022 | Jun 14, 2022 |
| DEFA14A | Additional proxy material | May 12, 2021 | — |
| DEF 14A | Proxy statement | Apr 9, 2021 | May 26, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 30, 2021 | Mar 30, 2021 |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEF 14A | Proxy statement | Apr 10, 2020 | May 20, 2020 |
| DEF 14A | Proxy statement | Apr 11, 2019 | May 28, 2019 |
| DEF 14A | Proxy statement | Apr 10, 2018 | May 10, 2018 |
| DEF 14A | Proxy statement | Apr 11, 2017 | May 15, 2017 |
| DEF 14A | Proxy statement | Apr 6, 2016 | May 12, 2016 |
| DEF 14A | Proxy statement | Apr 7, 2015 | May 7, 2015 |
| DEF 14C | Information statement | Oct 2, 2014 | Oct 2, 2014 |
| PRE 14C | Information statement | Sep 29, 2014 | Sep 22, 2014 |
| PRE 14C | Information statement | Sep 22, 2014 | Sep 22, 2014 |
| DEF 14A | Proxy statement | Apr 15, 2014 | Apr 15, 2014 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2014 | Apr 4, 2014 |
| DEF 14A | Proxy statement | Apr 2, 2013 | Apr 2, 2013 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2013 | Mar 19, 2013 |
| DEF 14A | Proxy statement | Apr 16, 2012 | Apr 16, 2012 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2012 | Apr 14, 2011 |
| DEF 14A | Proxy statement | Apr 14, 2011 | Apr 14, 2011 |
| DEF 14A | Proxy statement | Apr 16, 2010 | Apr 16, 2010 |
| DEF 14A | Proxy statement | Apr 22, 2009 | Apr 22, 2008 |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABEO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cleveland, OH
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 318306
- Former names
- PLASMATECH BIOPHARMACEUTICALS INC (until Jun 4, 2015); ACCESS PHARMACEUTICALS INC (until Aug 14, 2014); CHEMEX PHARMACEUTICALS INC (until Feb 5, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.